Picture of Protalix Biotherapeutics logo

PLX Protalix Biotherapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Protalix Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-18.3-6.52-27.6-14.98.31
Depreciation
Deferred Taxes
Non-Cash Items4.146.256.280.8562.81
Unusual Items
Other Non-Cash Items
Changes in Working Capital-6.83-27.19.9-12-10.5
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-19.4-26.1-10.3-25-1.32
Capital Expenditures-0.627-0.655-1.46-0.628-1.15
Purchase of Fixed Assets
Other Investing Cash Flow Items-0.256-19.320.4-4.41-15.6
Sale of Fixed Assets
Change in Net Investments
Other Investing Cash Flow
Cash from Investing Activities-0.883-2018.9-5.04-16.7
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities046.512.18.2424.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-200.47320.7-21.96.52